CADL Candel Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1841387 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-335.6%
TTM EPS YoY-173.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-93.6%
ROA-65.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets37.7%
Debt / equity0.00x
Current ratio7.57x
Interest coverage-13.30x
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-19.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $125,000 | $125,000 |
| R&D expense | $30.50M | $19.31M | $24.51M | $20.79M | $15.18M |
| SG&A expense | $17.77M | $14.06M | $13.88M | $14.06M | $10.67M |
| Operating income | -$48.27M | -$33.37M | -$38.39M | -$34.72M | -$25.73M |
| Interest expense | $2.12M | $2.09M | -$2.60M | $1.71M | — |
| Pretax income | -$38.18M | -$55.18M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$38.18M | -$55.18M | -$37.94M | -$18.79M | -$36.12M |
| EBITDA | -$47.42M | -$32.38M | -$37.43M | -$33.94M | -$25.49M |
| EPS (basic) | -0.72 | -1.74 | -1.31 | -0.65 | -1.91 |
| EPS (diluted) | -0.72 | -1.74 | -1.31 | -0.65 | -1.91 |
| Weighted avg. shares (diluted) | 52.96M | 31.68M | 28.94M | 28.82M | 18.87M |
| Balance sheet | |||||
| Cash & equivalents | $119.73M | $102.92M | $35.68M | $70.32M | $83.07M |
| Current assets | $121.39M | $103.80M | $36.80M | $71.94M | $84.94M |
| PP&E, net | $1.64M | $2.19M | $3.21M | $4.42M | $3.84M |
| Total assets | $125.19M | $106.87M | $41.20M | $77.69M | $89.20M |
| Current liabilities | $9.00M | $37.53M | $14.18M | $5.62M | $5.36M |
| Short-term debt | $0 | $9.89M | $8.89M | — | — |
| Long-term debt | — | $1.73M | $11.63M | — | $560,000 |
| Total debt | — | $11.63M | $20.52M | — | $560,000 |
| Total liabilities | $73.27M | $40.54M | $28.46M | $29.98M | $25.07M |
| Shareholders' equity | $51.92M | $66.33M | $12.74M | $47.71M | $64.14M |
| Net debt | — | -$91.29M | -$15.15M | — | -$82.51M |
| Shares outstanding | 54.90M | 46.81M | 29.09M | 28.92M | 28.69M |
| Cash flow statement | |||||
| Operating cash flow | -$38.31M | -$27.02M | -$34.24M | -$31.42M | -$22.22M |
| Capital expenditure | $587,000 | $16,000 | $457,000 | $1.30M | $1.83M |
| Free cash flow | -$38.90M | -$27.04M | -$34.70M | -$32.72M | -$24.05M |
| Investing cash flow | -$560,000 | -$16,000 | -$280,000 | -$1.30M | -$1.83M |
| Financing cash flow | $56.10M | $94.28M | -$121,000 | $19.97M | $71.80M |
| Depreciation & amortization | $845,000 | $990,000 | $960,000 | $778,000 | $232,000 |
| Stock-based compensation | $3.82M | $5.31M | $3.09M | $2.31M | $2.96M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.